Search Within

Mariana Da Silva Ferreira

Formats
  1. Journal Article (4)
  2. Meeting Abstract (2)
Groups
  1. Center for Hematologic Malignancies (6)
  2. Department of Medicine (6)
  3. Executive Committee, Center for Hematologic Malignancies (6)
  4. Hematologic Malignancies, Division of (6)
  5. Lymphoma (6)
  6. Sloan Kettering Institute Postdocs (6)

More Groups

People
  1. Anas Younes (6)
  2. Elisa De Stanchina (6)
  3. Zahra Asgari (5)
  4. Venkatraman Seshan (4)
  5. Ana Cadete Portelinha (3)
  6. Ingrid Erazo Andrade (3)

More People

Years
  1. 2023 (1)
  2. 2022 (2)
  3. 2021 (2)
  4. 2019 (1)
Publications
  1. Blood (2)
  2. Nature Communications (2)
  3. Cancer Research (1)
  4. Cell Reports Medicine (1)
Publishers
  1. American Society of Hematology (2)
  2. Nature Publishing Group (2)
  3. American Association for Cancer Research (1)
  4. Cell Press (1)

Results (6)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Synthetic lethality of drug-induced polyploidy and BCL-2 inhibition in lymphoma
    Journal Article

    Portelinha, A.; da Silva Ferreira, M.; Erazo, T.; Jiang, M.; Asgari, Z.; de Stanchina, E.; Younes, A.; Wendel, H. G.
    Nature Communications (2023)

    Fulltext@MSK | Save
  • Pharmacologically induced polyploidy triggers BCL2 dependence in lymphomas
    Meeting Abstract

    Portelinha, A.; da Silva Ferreira, M.; Erazo, T.; Asgari, Z.; de Stanchina, E.; Younes, A.; Wendel, H. G.
    Cancer Research (2022)

    Fulltext@MSK | Save
  • TP53 mutations and RNA-binding protein MUSASHI-2 drive resistance to PRMT5-targeted therapy in B-cell lymphoma
    Journal Article

    Erazo, T.; Evans, C. M.; Zakheim, D.; Chu, K. L.; Refermat, A. Y.; Asgari, Z.; Yang, X.; Da Silva Ferreira, M.; Mehta, S.; Russo, M. V.; more...
    Nature Communications (2022)

    Fulltext@MSK | Save
  • ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors
    Journal Article

    Portelinha, A.; Thompson, S.; Smith, R. A.; Da Silva Ferreira, M.; Asgari, Z.; Knezevic, A.; Seshan, V.; de Stanchina, E.; Gupta, S.; Denis, L.; more...
    Cell Reports Medicine (2021)

    Fulltext@MSK | Save
  • Tumor-targeted nanoparticles improve the therapeutic index of BCL2 and MCL1 dual inhibition
    Journal Article

    Bala Tannan, N.; Manzari, M. T.; Herviou, L.; Da Silva Ferreira, M.; Hagen, C.; Kiguchi, H.; Manova-Todorova, K.; Seshan, V.; de Stanchina, E.; Heller, D. A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Dual inhibition of MCL1 and BCL2 in lymphoma using tumor targeted nanoparticles
    Meeting Abstract

    Bala, N. B.; Taghizadeh Manzari, M.; Da Silva Ferreira, M.; Asgari, Z.; Hagen, C.; Seshan, V.; de Stanchina, E.; Manova-Todorova, K.; Heller, D.; Younes, A.
    Blood (2019)

    Fulltext@MSK | Save